Understanding TNM staging, differentiation grade, and how risk category drives your treatment plan
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Not every squamous cell carcinoma carries the same risk, and not every SCC is treated the same way. Two people can both be diagnosed with "SCC" and end up on very different paths — one with a simple in-office excision, another with wider surgical margins, imaging of the lymph nodes, or a consultation with a head and neck surgeon. What separates these paths is staging and grading.
These two systems answer different questions. Staging describes how far the tumor has grown and spread. Grading describes how abnormal the cancer cells look under the microscope. Together, they feed into a practical risk category — low, high, or very high risk — that actually drives the decisions your care team makes. This guide walks through both systems and explains why the risk category, more than a single number, is what matters most.
The American Joint Committee on Cancer (AJCC) staging manual, 8th edition, is the standard framework U.S. clinicians use to stage cutaneous SCC of the head and neck (the region it was specifically designed for). It scores three things: the primary Tumor (T), whether regional lymph Nodes are involved (N), and whether there's distant Metastasis (M).
T stage is based primarily on tumor size, plus a defined list of high-risk features:
High-risk features that can push a tumor to a higher T category on their own include depth greater than 6mm or invasion beyond the fat, perineural invasion (cancer tracking along a nerve), poor differentiation, and location on the ear or non-glabrous (hair-bearing) lip.
N stage classifies whether cancer has reached nearby lymph nodes, and if so, how many nodes, their size, which side of the neck, and whether the cancer has grown beyond the node's capsule (extranodal extension) — a feature associated with a higher risk of recurrence.
M stage simply indicates whether the cancer has spread to distant organs (M1) or not (M0). Distant metastasis from cutaneous SCC is uncommon overall but becomes more likely once a tumor has already reached the lymph nodes.
Separately from stage, a pathologist assigns a grade based on how closely the cancer cells resemble normal squamous cells under the microscope — a property called differentiation:
Differentiation isn't just a footnote — it's an independent risk factor. A small, poorly differentiated tumor can carry more concern than a larger, well-differentiated one, which is exactly why grade and stage are considered together rather than either one alone telling the full story.
In everyday practice, dermatologists and NCCN/AAD guidelines lean on a practical risk category — low-risk, high-risk, or very-high-risk — that synthesizes stage, grade, and additional clinical factors AJCC staging doesn't fully capture. This is often more useful day-to-day than the numeric stage alone, because it maps directly onto treatment decisions.
Tumor size (especially over 2 cm, and particularly over 4 cm), location (ear, lip, and other central-face "mask" areas carry extra weight), depth of invasion or thickness beyond 6mm, perineural or lymphovascular invasion, poor differentiation or aggressive subtypes on pathology, a tumor that has recurred after prior treatment, immunosuppression (such as organ transplant recipients), and prior radiation therapy to the area.
Low-risk SCC is typically treated with standard excision using narrower margins (often around 4-6mm) or, in appropriate cases, destruction techniques, followed by routine surveillance. High-risk and very-high-risk SCC generally call for wider surgical margins or Mohs micrographic surgery for maximal margin control, more frequent follow-up, and — depending on the specific features present — nodal imaging or a sentinel lymph node biopsy to check whether the cancer has silently reached nearby lymph nodes before that would be evident on exam. Adjuvant radiation is sometimes added for very-high-risk disease, particularly with perineural invasion or positive margins. See our treatment options guide for how these approaches compare.
Risk category also determines how closely you're followed afterward and how much attention is paid to the possibility of recurrence or spread. Our recurrence and metastasis risk guide and follow-up care guide go into how that surveillance schedule is built around your specific risk factors.
Staging and grading can sound like technical bookkeeping, but they translate directly into decisions that affect your care: how wide your surgical margins need to be, whether Mohs surgery is recommended over standard excision, whether your lymph nodes need to be imaged or sampled, and how closely you'll be watched afterward. The T, N, and M categories describe the tumor's extent; the grade describes how the cells behave; and your overall risk category — low, high, or very high — is where all of that comes together into a plan.
If you've had an SCC diagnosed, ask your dermatologist directly where your tumor falls on both scales. Understanding your specific risk category, rather than just hearing "you have skin cancer," is what lets you engage meaningfully in decisions about your treatment.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Only your pathology report and treating physician can determine your specific stage, grade, and risk category.
Chat with our AI guide for personalized information about SCC staging and risk categories
Chat with the Navigator